AG˹ٷ

STOCK TITAN

[8-K] Apyx Medical Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Bristow Group Inc. (VTOL) � Form 144 notice of proposed insider sale. An unnamed employee intends to sell 5,000 common shares through Morgan Stanley Smith Barney on or about 08 Aug 2025. At the latest quoted price, the block is valued at $187,729.50. Bristow reports 28.814 million shares outstanding, so the contemplated sale represents roughly 0.017 % of shares and is well below Rule 144 volume limits.

The shares were accumulated via the company’s Employee Stock Purchase Plan between 2015-2018; no other sales have occurred in the past three months. The filer affirms no knowledge of undisclosed adverse information. No new financial results or strategic developments are included; the filing solely discloses the insider’s intent to dispose of shares.

Bristow Group Inc. (VTOL) � Avviso di Formulario 144 per vendita interna proposta. Un dipendente non identificato intende vendere 5.000 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 08 agosto 2025. Al prezzo più recente quotato, il blocco azionario ha un valore di 187.729,50 $. Bristow riporta 28,814 milioni di azioni in circolazione, quindi la vendita prevista rappresenta circa lo 0,017 % delle azioni ed è ben al di sotto dei limiti di volume previsti dalla Regola 144.

Le azioni sono state accumulate tramite il Piano di Acquisto Azionario per Dipendenti della società tra il 2015 e il 2018; non sono state effettuate altre vendite negli ultimi tre mesi. Il dichiarante conferma di non avere conoscenza di informazioni negative non divulgate. Non sono inclusi nuovi risultati finanziari o sviluppi strategici; il deposito serve esclusivamente a comunicare l’intenzione dell’insider di vendere azioni.

Bristow Group Inc. (VTOL) � Aviso de Formulario 144 sobre propuesta de venta por parte de un insider. Un empleado no identificado planea vender 5.000 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 08 de agosto de 2025. Al último precio cotizado, el bloque tiene un valor de 187.729,50 $. Bristow reporta 28,814 millones de acciones en circulación, por lo que la venta propuesta representa aproximadamente el 0,017 % de las acciones y está muy por debajo de los límites de volumen establecidos por la Regla 144.

Las acciones fueron acumuladas mediante el Plan de Compra de Acciones para Empleados de la empresa entre 2015 y 2018; no se han realizado otras ventas en los últimos tres meses. El declarante afirma no tener conocimiento de información adversa no divulgada. No se incluyen nuevos resultados financieros ni desarrollos estratégicos; la presentación únicamente revela la intención del insider de vender acciones.

Bristow Group Inc. (VTOL) � 내부� 판매 예정� 대� Form 144 공지. 익명� 직원� Morgan Stanley Smith Barney� 통해 5,000 보통�� 2025� 8� 8� �� 매도� 계획입니�. 최근 공시� 가� 기준으로 해당 주식� 가치는 187,729.50 달러입니�. Bristow� 2,881� 4� �� 발행 주식� 보고했으�, 이번 매도� 전체 주식� � 0.017%� 해당하여 Rule 144� 거래 한도보다 훨씬 낮습니다.

해당 주식은 2015년부� 2018� 사이 회사� 직원 주식 구매 계획� 통해 축적되었으며, 지� 3개월 동안 다른 매도� 없었습니�. 신고자는 공개되지 않은 불리� 정보가 없음� 확인했습니다. 새로� 재무 결과� 전략� 개발 사항은 포함되지 않았으며, 이번 신고� 내부자의 주식 처분 의사만을 공개합니�.

Bristow Group Inc. (VTOL) � Avis de formulaire 144 concernant une vente proposée par un initié. Un employé non identifié prévoit de vendre 5 000 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 8 août 2025. Au dernier cours coté, le bloc est évalué à 187 729,50 $. Bristow rapporte 28,814 millions d’actions en circulation, ce qui fait que la vente envisagée représente environ 0,017 % des actions et reste largement en dessous des limites de volume de la règle 144.

Les actions ont été accumulées via le Plan d’Achat d’Actions Employés de la société entre 2015 et 2018 ; aucune autre vente n’a eu lieu au cours des trois derniers mois. Le déclarant affirme ne pas avoir connaissance d’informations défavorables non divulguées. Aucun nouveau résultat financier ou développement stratégique n’est inclus ; le dépôt vise uniquement à révéler l’intention de l’initié de céder ses actions.

Bristow Group Inc. (VTOL) � Form 144 Mitteilung über geplanten Insider-Verkauf. Ein nicht namentlich genannter Mitarbeiter beabsichtigt, 5.000 Stammaktien über Morgan Stanley Smith Barney etwa am 08. August 2025 zu verkaufen. Zum zuletzt notierten Kurs hat das Aktienpaket einen Wert von 187.729,50 $. Bristow meldet 28,814 Millionen ausstehende Aktien, sodass der geplante Verkauf etwa 0,017 % der Aktien entspricht und deutlich unter den Volumenbegrenzungen der Regel 144 liegt.

Die Aktien wurden im Zeitraum 2015 bis 2018 über den Mitarbeiteraktienkaufplan des Unternehmens erworben; in den letzten drei Monaten fanden keine weiteren Verkäufe statt. Der Einreichende bestätigt, keine Kenntnisse über nicht veröffentlichte nachteilige Informationen zu haben. Es werden keine neuen Finanzergebnisse oder strategischen Entwicklungen angegeben; die Meldung dient ausschließlich der Offenlegung der Absicht des Insiders, Aktien zu veräußern.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small insider sale (0.017 %)—administrative, immaterial for valuation.

The notice covers a routine disposal by an employee via Rule 144. Volume is negligible relative to float and daily trading volume, implying limited market impact. No price-sensitive data, guidance, or operational detail accompanies the filing. Taken alone, the action does not alter the investment thesis for VTOL and is generally viewed as neutral.

TL;DR: Insider selling through ESPP shares; governance posture unchanged.

The filer certifies awareness of Rule 10b5-1 and absence of undisclosed adverse information, supporting compliance hygiene. Because Bristow’s insider trading program permits orderly disposals under Rule 144, the transaction raises no governance red flags. Investors should monitor aggregate insider trends, but this single sale appears routine.

Bristow Group Inc. (VTOL) � Avviso di Formulario 144 per vendita interna proposta. Un dipendente non identificato intende vendere 5.000 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 08 agosto 2025. Al prezzo più recente quotato, il blocco azionario ha un valore di 187.729,50 $. Bristow riporta 28,814 milioni di azioni in circolazione, quindi la vendita prevista rappresenta circa lo 0,017 % delle azioni ed è ben al di sotto dei limiti di volume previsti dalla Regola 144.

Le azioni sono state accumulate tramite il Piano di Acquisto Azionario per Dipendenti della società tra il 2015 e il 2018; non sono state effettuate altre vendite negli ultimi tre mesi. Il dichiarante conferma di non avere conoscenza di informazioni negative non divulgate. Non sono inclusi nuovi risultati finanziari o sviluppi strategici; il deposito serve esclusivamente a comunicare l’intenzione dell’insider di vendere azioni.

Bristow Group Inc. (VTOL) � Aviso de Formulario 144 sobre propuesta de venta por parte de un insider. Un empleado no identificado planea vender 5.000 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 08 de agosto de 2025. Al último precio cotizado, el bloque tiene un valor de 187.729,50 $. Bristow reporta 28,814 millones de acciones en circulación, por lo que la venta propuesta representa aproximadamente el 0,017 % de las acciones y está muy por debajo de los límites de volumen establecidos por la Regla 144.

Las acciones fueron acumuladas mediante el Plan de Compra de Acciones para Empleados de la empresa entre 2015 y 2018; no se han realizado otras ventas en los últimos tres meses. El declarante afirma no tener conocimiento de información adversa no divulgada. No se incluyen nuevos resultados financieros ni desarrollos estratégicos; la presentación únicamente revela la intención del insider de vender acciones.

Bristow Group Inc. (VTOL) � 내부� 판매 예정� 대� Form 144 공지. 익명� 직원� Morgan Stanley Smith Barney� 통해 5,000 보통�� 2025� 8� 8� �� 매도� 계획입니�. 최근 공시� 가� 기준으로 해당 주식� 가치는 187,729.50 달러입니�. Bristow� 2,881� 4� �� 발행 주식� 보고했으�, 이번 매도� 전체 주식� � 0.017%� 해당하여 Rule 144� 거래 한도보다 훨씬 낮습니다.

해당 주식은 2015년부� 2018� 사이 회사� 직원 주식 구매 계획� 통해 축적되었으며, 지� 3개월 동안 다른 매도� 없었습니�. 신고자는 공개되지 않은 불리� 정보가 없음� 확인했습니다. 새로� 재무 결과� 전략� 개발 사항은 포함되지 않았으며, 이번 신고� 내부자의 주식 처분 의사만을 공개합니�.

Bristow Group Inc. (VTOL) � Avis de formulaire 144 concernant une vente proposée par un initié. Un employé non identifié prévoit de vendre 5 000 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 8 août 2025. Au dernier cours coté, le bloc est évalué à 187 729,50 $. Bristow rapporte 28,814 millions d’actions en circulation, ce qui fait que la vente envisagée représente environ 0,017 % des actions et reste largement en dessous des limites de volume de la règle 144.

Les actions ont été accumulées via le Plan d’Achat d’Actions Employés de la société entre 2015 et 2018 ; aucune autre vente n’a eu lieu au cours des trois derniers mois. Le déclarant affirme ne pas avoir connaissance d’informations défavorables non divulguées. Aucun nouveau résultat financier ou développement stratégique n’est inclus ; le dépôt vise uniquement à révéler l’intention de l’initié de céder ses actions.

Bristow Group Inc. (VTOL) � Form 144 Mitteilung über geplanten Insider-Verkauf. Ein nicht namentlich genannter Mitarbeiter beabsichtigt, 5.000 Stammaktien über Morgan Stanley Smith Barney etwa am 08. August 2025 zu verkaufen. Zum zuletzt notierten Kurs hat das Aktienpaket einen Wert von 187.729,50 $. Bristow meldet 28,814 Millionen ausstehende Aktien, sodass der geplante Verkauf etwa 0,017 % der Aktien entspricht und deutlich unter den Volumenbegrenzungen der Regel 144 liegt.

Die Aktien wurden im Zeitraum 2015 bis 2018 über den Mitarbeiteraktienkaufplan des Unternehmens erworben; in den letzten drei Monaten fanden keine weiteren Verkäufe statt. Der Einreichende bestätigt, keine Kenntnisse über nicht veröffentlichte nachteilige Informationen zu haben. Es werden keine neuen Finanzergebnisse oder strategischen Entwicklungen angegeben; die Meldung dient ausschließlich der Offenlegung der Absicht des Insiders, Aktien zu veräußern.

false 0000719135 0000719135 2025-08-07 2025-08-07
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 
August 7, 2025
 
Date of Report (date of earliest event reported)
apyx20240909_8kimg001.jpg
 
APYX MEDICAL CORPORATION
(Exact name of registrant as specified in its charter)
 
Delaware
001-31885
11-2644611
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
5115 Ulmerton Road, Clearwater, Florida 33760
(Address of principal executive offices, zip code)
(727) 384-2323
(Issuer's telephone number)
_____________________________________________________________
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Class A common stock
APYX
Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
 
 

 
Item 2.02         Results of Operations and Financial Condition
 
On August 7, 2025, Apyx Medical Corporation (the "Company") issued a press release reporting on its results of operations for the second quarter ended June 30, 2025. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
 
This information is intended to be furnished under Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01         Financial Statements and Exhibits
 
(d) Exhibits.
 
Exhibit No.
Description
 
99.1
Earnings press release dated August 7, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 7, 2025
Apyx Medical Corporation
 
       
 
By:
/s/ Matthew Hill
 
   
Matthew Hill
 
   
Chief Financial Officer, Secretary and Treasurer
 
 
 
Apyx Medical Corporation

NASDAQ:APYX

APYX Rankings

APYX Latest News

APYX Latest SEC Filings

APYX Stock Data

72.19M
32.14M
14.56%
43.84%
0.79%
Medical Devices
Surgical & Medical Instruments & Apparatus
United States
CLEARWATER